SG11201507739TA - Method for predicting sensitivity to egfr inhibitor - Google Patents

Method for predicting sensitivity to egfr inhibitor

Info

Publication number
SG11201507739TA
SG11201507739TA SG11201507739TA SG11201507739TA SG11201507739TA SG 11201507739T A SG11201507739T A SG 11201507739TA SG 11201507739T A SG11201507739T A SG 11201507739TA SG 11201507739T A SG11201507739T A SG 11201507739TA SG 11201507739T A SG11201507739T A SG 11201507739TA
Authority
SG
Singapore
Prior art keywords
egfr inhibitor
predicting sensitivity
predicting
sensitivity
egfr
Prior art date
Application number
SG11201507739TA
Other languages
English (en)
Inventor
Shiro Kitano
Takeshi Yamada
Original Assignee
Toppan Printing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toppan Printing Co Ltd filed Critical Toppan Printing Co Ltd
Publication of SG11201507739TA publication Critical patent/SG11201507739TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11201507739TA 2013-03-19 2014-03-19 Method for predicting sensitivity to egfr inhibitor SG11201507739TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013057033 2013-03-19
PCT/JP2014/057556 WO2014148557A1 (ja) 2013-03-19 2014-03-19 Ｅｇｆｒ阻害剤感受性予測方法

Publications (1)

Publication Number Publication Date
SG11201507739TA true SG11201507739TA (en) 2015-10-29

Family

ID=51580231

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201507739TA SG11201507739TA (en) 2013-03-19 2014-03-19 Method for predicting sensitivity to egfr inhibitor
SG10201707548RA SG10201707548RA (en) 2013-03-19 2014-03-19 Method for predicting sensitivity to egfr inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201707548RA SG10201707548RA (en) 2013-03-19 2014-03-19 Method for predicting sensitivity to egfr inhibitor

Country Status (6)

Country Link
US (1) US20160002741A1 (ja)
EP (1) EP2977464A4 (ja)
JP (1) JP6520705B2 (ja)
CN (1) CN105074009B (ja)
SG (2) SG11201507739TA (ja)
WO (1) WO2014148557A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129363A2 (en) 2011-03-24 2012-09-27 President And Fellows Of Harvard College Single cell nucleic acid detection and analysis
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
IL305303A (en) 2012-09-04 2023-10-01 Guardant Health Inc Systems and methods for detecting rare mutations and changes in number of copies
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
JP2015096049A (ja) * 2013-11-15 2015-05-21 凸版印刷株式会社 Ｖｅｇｆ阻害剤長期奏功性予測方法
CN106062214B (zh) 2013-12-28 2020-06-09 夸登特健康公司 用于检测遗传变异的方法和系统
WO2016103727A1 (ja) * 2014-12-25 2016-06-30 凸版印刷株式会社 特異的核酸配列の増幅促進方法
CN108603228B (zh) 2015-12-17 2023-09-01 夸登特健康公司 通过分析无细胞dna确定肿瘤基因拷贝数的方法
WO2017110764A1 (ja) * 2015-12-24 2017-06-29 公益財団法人がん研究会 マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー
WO2017187937A1 (ja) 2016-04-28 2017-11-02 デンカ株式会社 上皮性細胞成長因子受容体阻害剤に対する癌細胞の耐性を判定する方法
JP2019202936A (ja) * 2016-08-17 2019-11-28 中外製薬株式会社 抗Ｅｐｉｒｅｇｕｌｉｎ抗体と抗ＥＧＦＲ抗体との併用医薬
JP7215675B2 (ja) * 2017-01-16 2023-01-31 凸版印刷株式会社 腫瘍状態の評価方法
CN111032092A (zh) * 2017-06-30 2020-04-17 韩国科学技术院 Vegf-grab蛋白与药物的缀合物及其用途
WO2019043059A1 (en) * 2017-08-30 2019-03-07 Symphogen A/S COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER BY ANTI-EGFR ANTIBODIES
CN108998535B (zh) * 2018-09-11 2021-09-10 广州市宝创生物技术有限公司 一种kras基因多重突变位点检测试剂盒
MX2022006700A (es) 2019-12-02 2022-09-02 Storm Therapeutics Ltd Compuestos poliheterociclicos como inhibidores de mettl3.
CN112162042B (zh) * 2020-09-14 2022-04-26 首都医科大学附属北京朝阳医院 超高效液相色谱串联质谱测定血浆中amg510浓度的方法
CA3212669A1 (en) * 2021-03-09 2022-09-15 Janssen Biotech, Inc. Treatment of cancers lacking egfr-activating mutations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
EP2118322A2 (en) * 2007-03-13 2009-11-18 Amgen Inc. K-ras and b-raf mutations and anti-egfr antibody therapy
CA2680326A1 (en) * 2007-03-13 2008-09-18 Amgen Inc. K-ras mutations and anti-egfr antibody therapy
US20110320392A1 (en) * 2009-03-02 2011-12-29 Black Esther P Methods for predicting cancer response to egfr inhibitors
JP2012135290A (ja) * 2010-12-28 2012-07-19 Fuaruko Bio Syst:Kk 高感度Ｋ−ｒａｓ遺伝子変異解析法による分子標的薬の治療感受性の評価法
US20140134158A1 (en) * 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment

Also Published As

Publication number Publication date
EP2977464A1 (en) 2016-01-27
SG10201707548RA (en) 2017-10-30
WO2014148557A1 (ja) 2014-09-25
CN105074009A (zh) 2015-11-18
JP6520705B2 (ja) 2019-05-29
JPWO2014148557A1 (ja) 2017-02-16
CN105074009B (zh) 2017-09-26
US20160002741A1 (en) 2016-01-07
EP2977464A4 (en) 2016-10-19

Similar Documents

Publication Publication Date Title
SG10201707548RA (en) Method for predicting sensitivity to egfr inhibitor
HK1217973A1 (zh) 用於檢測病原體的快速方法
IL245935A0 (en) Methods for RNA analysis
HK1220190A1 (zh) 抑制劑
HK1248769A1 (zh) 預測間質性肺炎風險之方法
HK1217735A1 (zh) 用於單分子分析的方法
EP2972393A4 (en) BIOMARKERS AND METHOD FOR PREDICTING PREECLAMPSIA
GB201515089D0 (en) Method to perform rapid formation fluid analysis
HK1218014A1 (zh) 用以間接判定參考間距的方法
LU92173B1 (en) Distance determination method
GB201322365D0 (en) Improved method for repid analysis of gold
HK1212735A1 (zh) 用於評估免疫組庫的方法
GB201412190D0 (en) Method of optimization for an application
EP2972839A4 (en) PROCEDURE FOR DETECTING SUBSEQUENT SAMPLING EVENTS
SG11201506128YA (en) Method for measuring dissolved-substance concentration
PL3071969T3 (pl) Sposób analizy
BR112014025875A2 (pt) Método de medição
GB201314718D0 (en) Quantification method
GB201319875D0 (en) Method of measuring isotape ratio
EP2968395A4 (en) METHODS OF DETERMINING VIRAL SENSITIVITY TO VIRAL INHIBITORS
PT2821771T (pt) Método de teste
EP2981810C0 (en) METHOD FOR DETERMINING A PROPERTY OF A HETEROGENEUS MEDIUM
PL2979058T3 (pl) Sposób określania uszkodzenia pojazdu
HK1211626A1 (en) Predicting response to egfr inhibitors egfr
SG11201506096UA (en) Method for determining dissolved-hydrogen concentration